Stock listing
OTC:LYRA Lyra Therapeutics, Inc. Stock
Follow Lyra Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · OTC:LYRA
$0.03 USD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.03 – $0.03 USDNov 20, 2026
- Volume
- 434 sharesNov 20, 2026
- Market cap
- $53,246 USDAt the close on Nov 20, 2026 · price × 1.77M shares outstanding
- 52-week range
- $0.0004 – $4.59 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $118 USDMedian day 110 shares · 31 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:LYRA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 434 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 206 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 241 | |
| $0.03 | 0.00 | 0.0% | $0.03 | $0.03 | $0.03 | 266 | |
| $0.03 | -0.16 | -84.2% | $0.03 | $0.03 | $0.03 | 8,139 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.0004 | $0.195 | $0.0004 | 1,372 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.03 | $0.19 | $0.03 | 401 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.03 | $0.19 | $0.03 | 403 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.03 | $0.19 | $0.03 | 10,110 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.03 | $0.19 | $0.03 | 4,321 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.051 | $0.19 | $0.051 | 420 | |
| $0.19 | 0.00 | 0.0% | $0.0005 | $0.195 | $0.0005 | 1,637 | |
| $0.19 | -0.005 | -2.6% | $0.03 | $0.19 | $0.03 | 2,100 | |
| $0.195 | +0.005 | +2.6% | $0.03 | $0.195 | $0.03 | 2,102 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | 0.00 | 0.0% | $0.19 | $0.19 | $0.19 | 0 | |
| $0.19 | +0.04 | +26.7% | $0.145 | $0.19 | $0.142 | 317 | |
| $0.15 | 0.00 | 0.0% | $0.15 | $0.15 | $0.15 | 348 | |
| $0.15 | -0.05 | -25.0% | $0.03 | $0.15 | $0.03 | 2,678 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 213 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.051 | $0.20 | $0.051 | 600 | |
| $0.20 | 0.00 | 0.0% | $0.051 | $0.20 | $0.051 | 1,118 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.03 | $0.20 | $0.03 | 2,206 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | +0.01 | +5.3% | $0.20 | $0.20 | $0.20 | 110 | |
| $0.19 | -0.01 | -5.0% | $0.03 | $0.19 | $0.03 | 224 | |
| $0.20 | 0.00 | 0.0% | $0.45 | $0.52 | $0.20 | 5,469 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.20 | $0.20 | $0.20 | 0 | |
| $0.20 | 0.00 | 0.0% | $0.01 | $0.20 | $0.01 | 456 | |
| $0.20 | +0.19 | +1900.0% | $0.155 | $0.205 | $0.01 | 881 | |
| $0.01 | 0.00 | 0.0% | $0.01 | $0.01 | $0.01 | 1,011 | |
| $0.01 | 0.00 | 0.0% | $0.01 | $0.01 | $0.01 | 406 | |
| $0.01 | 0.00 | 0.0% | $0.01 | $0.01 | $0.01 | 1,046 | |
| $0.01 | 0.00 | 0.0% | $0.01 | $0.01 | $0.01 | 119 | |
| $0.01 | +0.01 | +2400.0% | $0.01 | $0.01 | $0.01 | 425 | |
| $0.0004 | 0.00 | 0.0% | $0.0004 | $0.0004 | $0.0004 | 815 |
Splits
1 split · OTC:LYRA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-50 | Consolidation |
- Ticker
- OTC:LYRA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
Lyra Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- Calls
- 4 calls with a replay · 4 with a transcript · latest Nov 9, 2021
- Decks
- 14 decks · latest September 2025
Valuation
EV/sales 36.2× against a median of 0.7×: 3rd lowest of 4 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 20, 2026
- Enterprise value
- $14.42M USD
- P/E
- Loss
- EV/sales
- 36.2×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 100.0%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.67
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Lyra Therapeutics, Inc. · OTC:LYRA | US$53,246 | US$14.42M | n/a | 36.2× | n/a | n/a | n/a | n/a | 0.67 |
| NKGen Biotech Inc. · OTC:NKGN | US$391,807 | US$38.58M | n/a | n/a | n/a | n/a | n/a | n/a | 0.88 |
| Vaxil Bio Ltd. · TSXV:VXL | US$319,500 | −US$4,070 | 1.2× | n/a | n/a | 0.4× | n/a | 0.0× | -0.16 |
| Chimeric Therapeutics Limited · ASX:CHM | US$292,816 | −US$220,193 | n/a | −0.1× | n/a | 0.2× | −262.8% | 2.5× | n/a |
| CERo Therapeutics Holdings, Inc. · OTC:CERO | US$265,035 | −US$190,890 | n/a | n/a | n/a | n/a | n/a | n/a | 1.47 |
| CDT Equity Inc. · NASDAQ:CDT | US$234,109 | −US$1.49M | n/a | n/a | n/a | 0.0× | n/a | 0.0× | 1.14 |
| GlucoTrack, Inc. · NASDAQ:GCTK | US$217,049 | −US$887,951 | n/a | n/a | n/a | n/a | n/a | n/a | 1.73 |
| Regen BioPharma, Inc. · OTC:RGBP | US$167,528 | US$167,289 | n/a | 0.7× | n/a | n/a | −501.4% | n/a | 1.20 |
| CNBX Pharmaceuticals Inc. · OTC:CNBX | US$160,577 | US$151,090 | n/a | n/a | n/a | n/a | n/a | n/a | 1.78 |
| Fifty 1 Labs Inc. · OTC:FITY | US$118,532 | US$282,021 | n/a | 6,000× | n/a | n/a | n/a | n/a | -1.17 |
| GB Sciences, Inc. · OTC:GBLX | US$81,414 | US$2.07M | n/a | n/a | n/a | n/a | n/a | n/a | -0.46 |
| Median of the others | US$225,579 | US$73,510 | 1.2× | 0.7× | 0.2× | −382.1% | 0.0× | 1.14 |
Forecasts
4 hold · Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 16.00 USD · Analysts' mean
- EPS, year to Dec 2025
- -25.66 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Maria Palasis | President and Chief Executive Officer |
Board
| Director | Role |
|---|---|
| Bradford Smith | Board Director |
| George Whitesides | Woodford L. and Ann A. Flowers University Professor, Harvard University |
| Jim Tobin | Lead Independent Director |
| Maria Palasis | President and Chief Executive Officer |
| Nancy L. Snyderman | Board Director |
| Robert Langer | David H. Koch Institute Professor, Massachusetts Institute of Technology |
Events
Calls
| Call | When | Status |
|---|---|---|
| Lyra Therapeutics (OTC:LYRA) Q3 2021 Earnings Call | Tue, Nov 09, 2021 · 4:30 PM ET | Replay |
| Lyra Therapeutics (OTC:LYRA) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 4:30 PM ET | Replay |
| Lyra Therapeutics (OTC:LYRA) Q1 2021 Earnings Call | Tue, May 11, 2021 · 4:30 PM ET | Replay |
| Lyra Therapeutics (OTC:LYRA) Q4 2020 Earnings Call | Tue, Mar 09, 2021 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2025 | Nov 12, 2025 · After close | −1.6% |
| Q2 2025 | Aug 12, 2025 · After close | +8.0% |
| Q1 2025 | May 6, 2025 · After close | +2.9% |
| Q4 2024 | Mar 19, 2025 · Before open | −0.6% |
| Q3 2024 | Nov 12, 2024 · After close | −28.0% |
| Q2 2024 | Aug 14, 2024 · After close | +1.1% |
| Q1 2024 | Apr 30, 2024 · After close | +1.7% |
| Q4 2023 | Mar 21, 2024 · After close | +2.8% |
| Q3 2023 | Nov 7, 2023 · After close | 0.0% |
| Q2 2023 | Aug 8, 2023 · After close | +2.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2023 | May 12, 2023 · Before open | −4.6% |
| Q4 2022 | Mar 29, 2023 · After close | +2.5% |
| Q3 2022 | Nov 8, 2022 · After close | −15.5% |
| Q2 2022 | Aug 9, 2022 · Before open | −4.1% |
| Q1 2022 | May 10, 2022 · Before open | +6.6% |
| Q4 2021 | Mar 9, 2022 · Before open | −5.3% |
| Q3 2021 | Nov 9, 2021 · After close | +2.8% |
| Q2 2021 | Aug 9, 2021 · After close | +0.1% |
| Q1 2021 | May 11, 2021 · After close | −1.7% |
| Quarter to Dec 31, 2020 | Mar 9, 2021 · After close | −6.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (September 2025) | Investor deck | 20 slides | September 2025 |
| Investor Presentation (August 2025) | Investor deck | 21 slides | Aug 12, 2025 |
| Investor Presentation (June 2025) | Investor deck | 26 slides | Jun 9, 2025 |
| Technical Presentation (June 2025) | Technical | 17 slides | Jun 2, 2025 |
| Investor Presentation (June 2025) | Investor deck | 25 slides | Jun 2, 2025 |
| Investor Presentation (January 2025) | Investor deck | 22 slides | Jan 10, 2025 |
| Technical Presentation (2025) | Technical | 17 slides | 2025 |
| Investor Presentation (August 2024) | Investor deck | 25 slides | Aug 14, 2024 |
| Investor Presentation (January 2024) | Investor deck | 23 slides | Jan 8, 2024 |
| 69th Annual Meeting of the American Rhinologic Society (ARS) 2023 | Conference | 12 slides | Sep 30, 2023 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (September 2023) | Technical | 13 slides | Sep 12, 2023 |
| Investor Presentation (March 2023) | Investor deck | 20 slides | Mar 29, 2023 |
| Technical Presentation (September 2022) | Technical | 21 slides | Sep 12, 2022 |
| Combined Otolaryngology Spring Meetings (COSM) 2021 | Conference | 15 slides | Apr 13, 2021 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 398.0K | 1.53M | 1.56M | 1.36M | 285.0K | 0 | 0 | 1.24M |
| Cost of revenue | 471.0K | 48.0M | 1.07M | 1.00M | 12.5M | 27.0K | ||
| Gross profit | 398.0K | 1.53M | 1.56M | 1.36M | 285.0K | -12.5M | -27.0K | 1.24M |
| Research and development | 18.4M | 43.8M | 48.0M | 38.8M | 29.7M | 12.5M | 12.0M | 4.97M |
| Selling, general and administrative | 11.5M | 18.5M | 19.1M | 17.6M | 14.2M | 9.69M | 4.49M | 3.53M |
| Operating income | -31.0M | -96.3M | -67.1M | -56.3M | -43.6M | -22.2M | -16.5M | -7.26M |
| Depreciation and amortization | 459.0K | 471.0K | 278.0K | 1.07M | 1.00M | 95.0K | 27.0K | 82.0K |
| EBITDA | -30.6M | -95.9M | -66.8M | -55.2M | -42.6M | -22.1M | -16.5M | -7.18M |
| Interest expense | 524.0K | 102.0K | 82.0K | 213.0K | 1.23M | |||
| Income before tax | -28.9M | -93.4M | -62.6M | -55.3M | -43.5M | -22.1M | -16.3M | -6.03M |
| Income tax | 11.0K | 39.0K | 59.0K | 13.0K | -1.10M | -82.0K | -213.0K | -1.23M |
| Net income | -28.9M | -93.4M | -62.7M | -55.3M | -42.4M | -22.1M | -16.3M | -6.03M |
| Earnings per share, basic | -1.86 | -1.43 | -1.26 | -1.83 | -3.27 | -2.58 | -1.99 | -0.96 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 15.9M | 40.6M | 22.4M | 32.5M | 45.7M | 74.6M | 9.81M | 23.9M |
| Short-term investments | 0 | 80.4M | 65.3M | 0 | ||||
| Receivables | 167.0K | |||||||
| Inventory | 1 | |||||||
| Current assets | 16.3M | 43.0M | 104.8M | 100.8M | 47.9M | 75.9M | 10.1M | 24.9M |
| Property, plant and equipment | 4.47M | 5.86M | 2.17M | 3.42M | 103.0K | |||
| Total assets | 36.1M | 66.3M | 142.6M | 110.0M | 54.9M | 80.8M | 15.0M | 25.4M |
| Accounts payable | 663.0K | 1.18M | 3.13M | 2.62M | 3.13M | 922.0K | 1.07M | 631.0K |
| Current liabilities | 9.52M | 12.6M | 19.6M | 14.5M | 18.2M | 4.88M | 5.21M | 1.96M |
| Total debt | 30.3M | 34.4M | 26.9M | 4.18M | 1.45M | 2.44M | 3.33M | |
| Total liabilities | 46.8M | 54.8M | 53.2M | 29.2M | 20.6M | 6.34M | 7.63M | 132.4M |
| Shareholders' equity | -10.7M | 11.6M | 89.4M | 80.8M | 34.3M | 74.5M | 7.33M | -107.1M |
| Shares outstanding | 15.5M | 65.1M | 49.8M | 30.2M | 13.0M | 8.59M | 8.18M | 6.27M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -28.9M | -70.0M | -63.3M | -43.4M | -25.8M | -21.1M | -13.8M | -6.64M |
| Capital spending | -116.0K | -2.34M | -1.05M | -164.0K | -3.38M | -1.77M | -211.0K | -37.0K |
| Free cash flow | -29.0M | -72.3M | -64.4M | -43.5M | -29.2M | -22.9M | -14.0M | -6.68M |
| Cash from investing | -98.0K | 80.3M | -12.6M | -65.0M | -3.38M | -1.77M | -211.0K | -37.0K |
| Cash from financing | 4.27M | 8.53M | 65.7M | 96.3M | 359.0K | 87.7M | -115.0K | 29.2M |
| Share buybacks | 57.5M | 111.0K | 29.0M | |||||
| Change in cash | -24.7M | 18.8M | -10.2M | -12.1M | -28.8M | 64.8M | -14.1M | 22.5M |
Cap table
Built by 6ix from Lyra Therapeutics, Inc.’s releases
- Common shares
- 1,774,882
- Fully diluted
- 1,774,882
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,774,882 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,774,882 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Robert Langer Other companies: Seer, Inc. (Director · Since at least Dec 3, 2020); Korro Bio, Inc. (Director · Oct 2, 2019 – Aug 17, 2022 · Past); Moderna, Inc. (Director · Dec 7, 2018 – May 6, 2024 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – Oct 14, 2019 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 12, 2018 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 21, 2016 · Past); Ocata Therapeutics Inc (Director · Oct 4, 2011 – Feb 10, 2016 · Past) | David H. Koch Institute Professor, Massachusetts Institute of Technology · Since at least Apr 30, 2020 |
| Don Elsey Other companies: BullFrog AI Holdings, Inc. (Director · Since at least Feb 13, 2023); RegeneRx Biopharmaceuticals, Inc. (Member of our Board of Directors · Since at least Sep 1, 2017); CapForce Inc. (Director · Feb 21, 2019 – Jun 7, 2023 · Past); Senseonics Holdings, Inc. (CFO, Secretary and Treasurer · Apr 12, 2016 – Feb 2, 2018 · Past) | CFO, Treasurer & Secretary · Apr 30, 2020 – Feb 8, 2021 · Past |
| C Ann Merrifield Other companies: Juniper Pharmaceuticals Inc (Director · Jul 16, 2015 – Aug 14, 2018 · Past); InVivo Therapeutics Holdings Corp (Director · Nov 8, 2014 – Nov 17, 2022 · Past); Flexion Therapeutics Inc (Director · Jun 11, 2014 – Nov 19, 2021 · Past) | Director · Apr 30, 2020 – May 14, 2025 · Past |
| James R. Tobin Other companies: TransMedics Group, Inc. (Director · Since at least Feb 9, 2021); Globus Medical, Inc. (Director · Since at least Jan 14, 2021); Oxford Immunotec Global PLC (Director · Mar 8, 2021 – Mar 8, 2021 · Past) | Lead Independent Director · Since at least Mar 4, 2022 |
| John Bishop Other companies: Ardelyx, Inc. (Chief Technical and Quality Officer · Since at least Aug 1, 2025); Forma Therapeutics Holdings Inc (SVP, Chief Technology Officer · Jun 14, 2021 – Oct 14, 2022 · Past); Momenta Pharmaceuticals Inc (Senior VP, Pharmaceutical Scie · Feb 17, 2006 – May 19, 2016 · Past) | Chief Technology Officer · Feb 27, 2023 – Jan 30, 2024 · Past |
| Michael Seth Altman Other companies: ARYA Sciences Acquisition IV Corp (Chief Financial Officer, Director · Jul 31, 2024 – Jul 31, 2024 · Past); Freenome, Inc. (Chief Business Officer, Director · Jun 11, 2024 – Jun 13, 2024 · Past); Nautilus Biotechnology, Inc. (Director · Jun 15, 2022 – Jun 14, 2024 · Past) | Director · Jun 16, 2022 – Jun 13, 2024 · Past |
| Nancy L. Snyderman Other companies: Alkermes plc (Director · Since at least May 23, 2018); Future Health Esg Corp (Director · Sep 9, 2021 – Oct 24, 2021 · Past); Axonics Modulation Technologies Inc (Director · Apr 8, 2019 – Aug 24, 2020 · Past) | Board Director · Since at least Oct 27, 2020 |
| Maria Palasis Other companies: Beta Bionics, Inc. (Board Member · Since at least Jan 29, 2025) | President and Chief Executive Officer · Since at least Apr 30, 2020 |
| Bradford Smith | Board Director · Since at least Nov 5, 2026 |
| Corinne Noyes | See Remarks · Apr 30, 2020 – Jan 31, 2023 · Past |
All 14 people
| Person | Seat |
|---|---|
| George Whitesides | Woodford L. and Ann A. Flowers University Professor, Harvard University · Since at least Nov 5, 2026 |
| Jason Cavalier | Principal Financial Officer · Since at least Sep 13, 2021 |
| Pamela E Nelson | SVP, Regulatory Affairs · Aug 3, 2020 – Feb 12, 2022 · Past |
| Robert E Richard | SVP, Technical Operations · Jun 24, 2020 – Jan 31, 2023 · Past |
Log in to ask 6ix AI your own questions about Lyra Therapeutics, Inc.